WO2017177907A1 - Vaccins contre les tumeurs pd-l1 et pd-l2 de point de contrôle immunitaire - Google Patents
Vaccins contre les tumeurs pd-l1 et pd-l2 de point de contrôle immunitaire Download PDFInfo
- Publication number
- WO2017177907A1 WO2017177907A1 PCT/CN2017/080143 CN2017080143W WO2017177907A1 WO 2017177907 A1 WO2017177907 A1 WO 2017177907A1 CN 2017080143 W CN2017080143 W CN 2017080143W WO 2017177907 A1 WO2017177907 A1 WO 2017177907A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- recombinant protein
- patient
- cells
- construct
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 83
- 229960005486 vaccine Drugs 0.000 title claims description 32
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 149
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 149
- 230000003308 immunostimulating effect Effects 0.000 claims abstract description 26
- 229940126546 immune checkpoint molecule Drugs 0.000 claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims description 193
- 239000012634 fragment Substances 0.000 claims description 71
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 61
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 58
- 108020004707 nucleic acids Proteins 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 150000007523 nucleic acids Chemical class 0.000 claims description 45
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 41
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 41
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 41
- 239000013598 vector Substances 0.000 claims description 37
- 238000000034 method Methods 0.000 claims description 34
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 33
- 210000002865 immune cell Anatomy 0.000 claims description 26
- 230000009261 transgenic effect Effects 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 25
- 230000001900 immune effect Effects 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 241000700605 Viruses Species 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 108010040721 Flagellin Proteins 0.000 claims description 18
- 230000003053 immunization Effects 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 13
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 12
- 230000004044 response Effects 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000002671 adjuvant Substances 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 230000016784 immunoglobulin production Effects 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 241001138401 Kluyveromyces lactis Species 0.000 claims description 4
- 241000235648 Pichia Species 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 210000004698 lymphocyte Anatomy 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 8
- 102000037982 Immune checkpoint proteins Human genes 0.000 abstract description 5
- 108091008036 Immune checkpoint proteins Proteins 0.000 abstract description 5
- 102000008096 B7-H1 Antigen Human genes 0.000 description 59
- 210000004881 tumor cell Anatomy 0.000 description 50
- 239000000427 antigen Substances 0.000 description 46
- 108091007433 antigens Proteins 0.000 description 46
- 102000036639 antigens Human genes 0.000 description 46
- 238000004519 manufacturing process Methods 0.000 description 34
- 230000028993 immune response Effects 0.000 description 27
- 230000002147 killing effect Effects 0.000 description 21
- 238000002649 immunization Methods 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 229910052804 chromium Inorganic materials 0.000 description 7
- 239000011651 chromium Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 210000003000 inclusion body Anatomy 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000048776 human CD274 Human genes 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 230000005909 tumor killing Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229940029030 dendritic cell vaccine Drugs 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000001483 mobilizing effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 description 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 1
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 229940032219 immunotherapy vaccine Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009495 transient activation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 229940030325 tumor cell vaccine Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to the field of bioengineering, and in particular, to recombinant proteins and uses thereof.
- Targeted therapies mainly include monoclonal antibodies (sometimes classified as passive cell transfusion and tumor vaccines, immunotherapy through the immune system of the motivational body, enhanced tumor microenvironment anti-tumor immunotherapy) and small molecule targeted drugs, while immunotherapy It mainly includes cytokine therapy, immunoassay monoclonal antibody, and adoptive immunotherapy to control and kill tumor cells. Therefore, it has the advantages of high efficiency, high specificity and good tolerance, and has broad prospects in cancer therapy.
- Tumor immunotherapy vaccines mainly include tumor cell vaccines, dendritic cell (DC cell) vaccines, protein & peptide vaccines, nucleic acid vaccines, genetically engineered vaccines and anti-idiotype tumor vaccines.
- the main mechanism by which these vaccines can kill tumors is through The patient is directed against a tumor-specific antigen immune response, including antibody response and cytotoxic T lymphocyte (CTL) specific killing.
- CTL cytotoxic T lymphocyte
- tumor vaccines target tumor-associated antigens, and their clinical efficacy is weak, and further research and development are needed to enhance clinical efficacy.
- Tumor cells highly express immune checkpoint molecules PD-L1 or PD-L2, and activated cytotoxic T lymphocytes on the surface
- PD-1 which inhibits the T lymphocyte response of the tumor, escapes the immune killing of cytotoxic T lymphocytes.
- CTL immune cells-cytotoxic T lymphocytes
- an object of the present invention is to provide a recombinant PD-L1 protein having an immune response which causes a tumor-specific antigen, which is actively stimulated to produce an anti-PD-L1 antibody in a patient, and the patient has been mobilized.
- the presence of spontaneously induced immune cell CTLs is induced and stimulates the production of new anti-PD-L1 CTLs, which in turn specifically kill tumor cells.
- the active immune killing effect on tumor cells caused by the recombinant protein proposed by the invention is remarkable.
- the invention proposes a recombinant protein.
- the recombinant protein comprises: an immunological checkpoint molecule fragment; a helper T cell epitope fragment; and an immunostimulatory molecule fragment.
- the recombinant protein proposed in the embodiments of the present invention can continuously stimulate the production of anti-immunization checkpoint antibodies in vivo, mobilize the spontaneously induced immune cell CTLs existing in the body, and stimulate the production of CTLs against the immune checkpoints, thereby specifically killing the tumor cells. .
- the active immune killing effect on tumor cells caused by the recombinant protein proposed by the embodiments of the present invention is remarkable.
- the recombinant protein may further comprise at least one of the following additional technical features:
- the immune checkpoint molecule is PD-L1 or PD-L2.
- PD-L1 or PD-L2 is specifically expressed in tumor cells, and the specificity of the tumor antigen immune response caused by the recombinant protein proposed in the examples of the present invention is stronger.
- the immunological checkpoint molecule fragment is an extracellular molecular fragment of the PD-L1 or PD-L2 removal transmembrane region.
- the extracellular molecular fragment of PD-L1 or PD-L2 in the transmembrane region has only tumor antigenicity and does not have tumor immunosuppressive function, and thus the extracellular molecular fragment of PD-L1 or PD-L2 in the transmembrane region can be further removed.
- the specificity is further improved.
- the helper T cell epitope is a broad spectrum PADRE helper T cell epitope.
- Broad-spectrum PADRE-assisted T cell epitopes can effectively activate helper T cells, thereby further enhancing the specific killing of cytotoxic T lymphocytes (CTLs) caused by recombinant proteins.
- CTLs cytotoxic T lymphocytes
- the immunostimulatory molecule is a flagellin.
- the immunostimulatory molecule has biological activity, can significantly enhance the antigen presenting function of dendritic cells (DC cells) and enhance the activity of cytotoxic T lymphocytes (CTLs) and B lymphocytes, and further the recombinant protein of the embodiments of the present invention can be further To effectively cause tumor antigen immune response.
- DC cells dendritic cells
- CTLs cytotoxic T lymphocytes
- B lymphocytes cytotoxic T lymphocytes
- the N-terminus of the immunological checkpoint molecule fragment is linked to the C-terminus of the immunostimulatory molecule fragment, and the C-terminus of the immunological checkpoint molecular fragment and the N-terminus of the helper T cell epitope fragment Connected.
- the related molecular fragment in the recombinant protein of the embodiment of the present invention is beneficial to the tumor antigen PD-L1 or PD-L2 in the above-mentioned linked state.
- the presentation of the fragment in the DC cell facilitates the function of the helper T cell epitope and the immunostimulatory molecule to activate the immune cell, and the recombinant protein of the embodiment of the present invention can more effectively induce the tumor antigen immune response.
- the invention proposes a recombinant protein.
- the recombinant protein has the amino acid sequence of SEQ ID NOS: 1-3.
- the recombinant protein proposed in the embodiment of the present invention can cause a tumor-specific antigen immune response, and the protein stimulates the production of anti-PD-L1 or PD-L2 antibody in the patient by active immunization, and mobilizes the spontaneous induction of the existing in the patient.
- the cells are immunized with CTL and stimulated to produce anti-PD-L1 or PD-L2 CTL, thereby specifically killing tumor cells.
- the active immune killing effect on tumor cells caused by the recombinant protein proposed by the invention is remarkable.
- the invention proposes a nucleic acid.
- the nucleic acid encodes the recombinant protein described above, and the nucleic acid has the nucleotide sequence shown in SEQ ID NOS: 4-6.
- the recombinant protein encoded by the nucleic acid according to the embodiment of the present invention stimulates the production of anti-PD-L1 or PD-L2 antibody in the patient by active immunization, mobilizes the spontaneously induced immune cell CTL which has already existed in the patient, and stimulates the production of anti-drug.
- PD-L1 or PD-L2CTL which specifically kills tumor cells.
- the active immune killing effect on tumor cells caused by the recombinant protein proposed by the invention is remarkable.
- the invention proposes a construct.
- the construct carries a nucleic acid as described above.
- the construct introduced into the recipient cell of the present invention can achieve high-efficiency expression of the nucleic acid described above, and thereby efficiently express the recombinant protein described above in the recipient cell.
- the construct may further comprise at least one of the following additional technical features:
- the vector of the construct is a pET series vector, a pPIC series vector, a BacPAK, a pSV series vector or a pCMV series vector.
- the above vector of the embodiment of the present invention can achieve further efficient expression of the above recombinant protein in prokaryotic cells or eukaryotic cells.
- the invention proposes a construct.
- the construct carries the following nucleic acid molecule: (1) a nucleic acid molecule encoding a fragment of an immunological checkpoint molecule having the amino acid sequence set forth in SEQ ID NOS: 7-9, The nucleic acid molecule encoding the immunological checkpoint molecule fragment has the nucleotide sequence shown in SEQ ID NOS: 10 to 12; (2) the nucleic acid molecule encoding the helper T cell epitope fragment, the helper T cell epitope The fragment has the amino acid sequence set forth in SEQ ID NO: 13, the nucleic acid molecule encoding the helper T cell epitope fragment having the nucleotide sequence set forth in SEQ ID NO: 14; and (3) encoding the immunostimulatory A nucleic acid molecule of a molecular fragment having the amino acid sequence of SEQ ID NO: 15, the nucleic acid molecule encoding the immunostimulatory molecule fragment having the
- the construct according to the embodiment of the present invention efficiently expresses a recombinant protein containing an immunological checkpoint molecular fragment, a helper T cell epitope fragment and an immunostimulatory molecule fragment in a recipient cell, and the recombinant protein is actively immunized in a patient. Stimulate the production of anti-PD-L1 antibody, mobilize the spontaneously induced immune cell CTL already existing in the patient, and stimulate the production of anti-PD-L1CTL, thereby specifically killing the tumor cells.
- the invention provides a transgenic cell.
- the transgenic cell carries a construct as described above.
- the transgenic cells proposed in the embodiments of the present invention can express the recombinant protein as described above, and the obtained recombinant protein stimulates an anti-immunological checkpoint, such as PD-L1 or PD-L2 antibody, by active immunization, and mobilizes.
- an anti-immunological checkpoint such as PD-L1 or PD-L2 antibody
- Spontaneously induced immune cell CTLs already present in the patient and stimulate the production of anti-immunological checkpoints, such as PD-L1 or PD-L2 CTL, which specifically kill tumor cells.
- the transgenic cell may further comprise at least one of the following additional technical features:
- the transgenic cells are BL21, BL21 (DE3), BL21 (DE3) pLysS, DH10B, XL1-Blue, Pichia pastors, Kluyveromyces lactis, Sf9, Sf21, High-Five T, CHO cell line, HEK cell line, Hela cell line or COS cell line.
- the transgenic cell can efficiently express the recombinant protein described above, and then the recombinant protein obtained by protein purification can be administered to a patient, and the patient can be further effectively stimulated to produce anti-PD in the patient by active immunization.
- the -L1 or PD-L2 antibody mobilizes spontaneously induced immune cell CTLs already present in the patient and stimulates the production of anti-PD-L1 or PD-L2CTL, thereby specifically killing the tumor cells.
- the transgenic cell is an antigen presenting cell.
- the antigen presenting cell is derived from a patient, and the antigen presenting cell carrying the aforementioned construct can be further input into the patient, thereby realizing the continuous expression of the recombinant protein described above in the patient, and further Actively immunizing in the body to produce anti-PD-L1 or PD-L2 antibodies in vivo, mobilizing the spontaneously induced immune cell CTLs already present in the patient, and stimulating the production of anti-PD-L1 or PD-L2CTL, Specific killing of tumor cells.
- the transgenic cell is a DC cell.
- the DC cells have an antigen-presenting function, and the DC cells derived from the patient themselves carry the aforementioned construct and are returned to the patient, thereby realizing the high-efficiency expression of the recombinant protein described above in the patient and the tumor antigen PD-L1.
- PD-L2 is efficiently presented on the surface of DC cells, thereby further effectively stimulating the production of anti-PD-L1 or PD-L2 antibodies, mobilizing the spontaneously induced immune cell CTLs already present in the patient, and stimulating the production of anti-PD-L1 or PD -L2CTL, which further effectively kills tumor cells specifically.
- the invention provides the use of the aforementioned recombinant protein for the preparation of a medicament,
- the drug is used to prevent or treat a tumor.
- the recombinant protein proposed by the embodiments of the present invention can cause a significant tumor-specific antigen immune response in a tumor patient, and effectively stimulates the production of an anti-immunological checkpoint, such as PD-L1 or PD-L2 antibody, to mobilize the spontaneous induction already existing in the patient.
- the resulting immune cell CTL is stimulated to produce an anti-immunological checkpoint, such as PD-L1 or PD-L2CTL, which effectively kills the tumor cells specifically.
- the recombinant protein proposed in the examples of the present invention has utility in the preparation of a medicament effective for preventing or treating a tumor.
- the invention provides the use of a recombinant protein as described above for the preparation of a vaccine for the prevention or treatment of a tumor.
- the recombinant protein proposed by the embodiments of the present invention can cause a significant tumor-specific antigen immune response in a tumor patient, and effectively stimulates the production of an anti-immunological checkpoint, such as PD-L1 or PD-L2 antibody, to mobilize the spontaneous induction already existing in the patient.
- the resulting immune cell CTL is stimulated to produce an anti-immunological checkpoint, such as PD-L1 or PD-L2CTL, which effectively kills the tumor cells specifically.
- the recombinant protein proposed in the examples of the present invention has a use in preparing a vaccine effective for preventing or treating a tumor.
- the invention provides the use of a recombinant protein as described above for the preparation of a vaccine for the treatment of a viral infection.
- the inventors have found that HBV, HCV, HIV, EBV virus-infected cells express PD-L1, and the vaccine prepared by the recombinant protein of the present invention can stimulate anti-PD-L1 in a patient.
- the antibody mobilizes spontaneously induced immune cell CTLs already present in the patient and stimulates the production of anti-immunological checkpoints, such as PD-L1 CTL, to effectively kill cells infected with the above virus.
- the invention provides a pharmaceutical composition.
- the pharmaceutical composition comprises: the recombinant protein described above; and a pharmaceutically acceptable adjuvant.
- the recombinant protein in the pharmaceutical composition proposed in the examples of the present invention can cause a significant specific antigen immune response, and the function of the adjuvant to enhance the immune response.
- the pharmaceutical composition provided by the embodiment of the present invention effectively stimulates an anti-immunization checkpoint, such as a PD-L1 or PD-L2 antibody, to mobilize an already existing spontaneously induced immune cell in a patient. CTL, and stimulate the production of anti-immunological checkpoints, such as PD-L1 or PD-L2CTL, to effectively kill tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
- viruses HBV, HCV, HIV, EBV
- the invention proposes a DC cell.
- the DC cells are loaded with the recombinant protein described above.
- the DC cells proposed in the embodiments of the present invention can present antigens in the recombinant protein (such as the immunological checkpoint molecular fragment described above), helper T cell epitope fragments, and immunostimulatory molecule fragments, respectively.
- anti-immunological checkpoints such as PD-L1 or PD-L2 antibodies
- mobilizes spontaneously induced immune cell CTLs already present in patients and stimulates the production of anti-immune checkpoints such as PD-L1 or PD-L2CTL, in turn, effectively kills tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
- viruses HBV, HCV, HIV, EBV
- the invention provides a targeted immune cell population.
- the targeted immune cell population is obtained by co-culture of DC cells with lymphocytes as described above. According to this issue
- the targeted immune cell population proposed in the embodiments of the present invention can specifically kill tumor cells, secrete antibodies that specifically bind tumor antigens, and achieve specific removal of tumor cells.
- the invention proposes a vaccine.
- the vaccine comprises a recombinant protein as described above, a DC cell as described above or a targeted immune cell population as described above.
- the recombinant protein, DC cell, and targeted immune cell population proposed in the examples of the present invention can cause a significant specific antigen immune response in a patient.
- the vaccine according to the embodiment of the present invention can effectively stimulate the production of an anti-immunization checkpoint, such as a PD-L1 or PD-L2 antibody, mobilize the spontaneously induced immune cell CTL already existing in the patient, and stimulate An anti-immunization checkpoint, such as PD-L1 or PD-L2CTL, is generated to effectively kill tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
- an anti-immunization checkpoint such as a PD-L1 or PD-L2 antibody
- the invention provides an antibody.
- the antibody specifically recognizes the recombinant protein described above, and the antibody proposed in the embodiment of the present invention specifically recognizes a tumor antigen.
- the present invention finds that the antibody specifically recognizes an antigen, specifically binds to a tumor cell or a cell infected by a virus (HBV, HCV, HIV, EBV), thereby causing a tumor cell or a virus (HBV) Cells infected with HCV, HIV, EBV) are engulfed by phagocytic cells to achieve specific clearance of tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
- a virus HCV, HCV, HIV, EBV
- the invention provides a method of preparing an antibody.
- the method comprises: immunizing an animal with the recombinant protein described above; collecting serum of the immunized animal; and purifying the antibody of interest from the serum.
- the method for preparing an antibody proposed in the embodiments of the present invention is simple and convenient, and the antibody can specifically recognize the recombinant protein.
- the invention provides a therapeutic composition.
- the therapeutic composition comprises: a recombinant protein as described above, a nucleic acid as described above, a construct as described above, a transgenic cell as described above, a pharmaceutical composition as described above, a front The DC cells, the aforementioned targeted immune cell population, the vaccine described above or the antibodies described above.
- the therapeutic composition proposed by the embodiments of the present invention can directly or indirectly cause a specific antigen immune response, and achieve specificity to tumor cells or cells infected by viruses (HBV, HCV, HIV, EBV). Kill and clear.
- the invention provides a method of stimulating anti-PD-L1 antibody production or cytotoxic T lymphocyte response in a patient.
- the method is achieved by at least one of the following: 1) the recombinant protein described above is co-cultured with DC cells taken from a patient, and the DC of the recombinant protein described above is loaded The cells are returned to the patient; 2) the patient is administered the pharmaceutical composition described above; 3) the previously described construct is introduced into the DC cells taken from the patient, and the DC cells introduced into the construct are returned to the patient. In vivo; and 4) administering to the patient a construct as described above.
- the manner proposed in the examples of the present invention can significantly stimulate anti-PD-L1 antibody production or cytotoxic T lymphocyte reaction in a patient.
- the invention provides a method of treating cancer. According to an embodiment of the present invention, it is achieved by at least one of the following methods: 1) the recombinant protein described above is co-cultured with DC cells taken from a cancer patient, and the DC cells loaded with the recombinant protein described above are returned. Loss to a cancer patient; 2) administration of the aforementioned pharmaceutical composition to a cancer patient; 3) introduction of the aforementioned construct into DC cells taken from a cancer patient, and returning DC cells introduced into the construct to In vivo in a cancer patient; and 4) administration of the aforementioned construct to a cancer patient.
- the method proposed by the embodiments of the present invention can directly or indirectly cause a specific antigen immune response, and achieve specific killing and elimination of tumor cells.
- the invention provides a method of treating a patient infected with a virus.
- it is achieved by at least one of the following methods: 1) the recombinant protein described above is co-cultured with DC cells taken from a patient, and the DC cells loaded with the recombinant protein described above are returned.
- the patient is administered the construct described above.
- the method proposed by the embodiments of the present invention can directly or indirectly cause a specific antigen immune reaction, and achieve specific killing and elimination of cells infected by viruses (HBV, HCV, HIV, EBV), thereby effectively treating patients infected with the virus.
- the above method may further include at least one of the following additional technical features:
- the virus comprises at least one selected from the group consisting of HBV, HCV, HIV and EBV. Further effective treatment of patients infected with HBV, HCV, HIV or EBV can be achieved using the above method according to an embodiment of the invention.
- FIG. 1 is a schematic view showing the structure of a fusion protein (Flagellin-human PD-L1/L2 ⁇ -PADRE Th) according to an embodiment of the present invention
- fusion protein Flagellin-human PD-L1 ⁇ -PADRE Th
- a DC vaccine loaded with a fusion protein Flagellin-human PD-L1 ⁇ -PADRE Th capable of significantly inducing an anti-PD-L1 CTL reaction according to an embodiment of the present invention
- PD-L1 + lung cancer is a DC vaccine loaded with a fusion protein (Flagellin-Human PD-L1 ⁇ -PADRE Th) capable of significantly controlling the growth of PD-L1 + lung cancer according to an embodiment of the present invention.
- a fusion protein Flagellin-Human PD-L1 ⁇ -PADRE Th
- first and second are used for descriptive purposes only, and are not to be construed as indicating or implying a relative importance or implicitly indicating the number of technical features indicated. Thus, features defining “first” and “second” may include one or more of the features either explicitly or implicitly. Further, in the description of the present invention, the meaning of "a plurality" is two or more unless otherwise specified.
- the invention proposes a recombinant protein.
- the recombinant protein comprises: an immunological checkpoint molecule fragment; a helper T cell epitope fragment; and an immunostimulatory molecule fragment.
- the recombinant protein proposed in the embodiments of the present invention stimulates the production of anti-immunological checkpoint antibodies in the patient, mobilizes the spontaneously induced immune cell CTLs already existing in the body, and stimulates the production of CTLs against the immune checkpoints, thereby specifically killing the tumor cells.
- the active immune killing effect on tumor cells caused by the recombinant protein proposed by the embodiments of the present invention is remarkable.
- the immune checkpoint molecule may be selected from, but not limited to, at least one of PD-L1 and PD-L2.
- PD-L1 or PD-L2 is specifically expressed in tumor cells, and the specificity of the tumor antigen immune response caused by the recombinant protein proposed in the examples of the present invention is stronger.
- the immunological checkpoint molecule fragment is an extracellular molecular fragment (PD-L1 ⁇ /PD-L2 ⁇ ) of the transmembrane region of the PD-L1 or PD-L2.
- the extracellular molecular fragment of the PD-L1 or PD-L2 removal transmembrane region has only tumor antigenicity and does not have tumor immunosuppressive function, and then the extracellular molecular fragment of the transmembrane region of PD-L1 or PD-L2 is antigen-removed.
- Presenting cells such as DC cells are presented on the surface of the cells, which can effectively elicit a tumor antigen immune response, and the specificity is further improved.
- the helper T cell epitope can be a broad spectrum PADRE helper T cell epitope (PADRE Th).
- PADRE Th PADRE helper T cell epitope
- the broad-spectrum PADRE helper T cell epitope is an epitope peptide that binds to a broad spectrum of human leukocyte antigen DR (HLA-DR) with high affinity or intermediate affinity and 16 of the most prevalent HLA- 15 of the DR types are combined. Because of its universal binding, PADRE needs to overcome the problems caused by the diversity of HLA-DR molecules in the population. PADRE acts as a helper T cell epitope and binds to the antigen. After binding, it activates the Ag-specific antigen reaction efficiently and for a long time.
- HLA-DR human leukocyte antigen DR
- the PADRE peptide is specifically processed to immunologically activate helper T lymphocyte 1 (Th1) in humans to assist in the activation of killer immune T cells and to activate helper T lymphocyte 2 (Th2) to assist B lymphocytes to secrete antibodies, thereby Further enhancing the antigenic immune response caused by the recombinant protein.
- Th1 helper T lymphocyte 1
- Th2 helper T lymphocyte 2
- the immunostimulatory molecule may be selected from Flagellin.
- the immunostimulatory molecule is biologically active.
- Flagellin (toll-like receptor 5 ligand, TLR5L) is the major protein of bacterial flagella and is a highly conserved bacterial protein. Flagellin regulates TLR-5-dependent signaling in mammalian cells and induces immune responses, including the production of pro-immune cytokines and co-stimulatory molecules that upregulate antigen presenting cells (APS).
- Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) expressed in various cells, especially in immune cells such as monocytes and macrophages. In cells, DC cells and lymphocytes. TLRs detect pathogen-associated molecules (PAMPs) and bind to innate immune cells to cause maturation and activation of these immune cells, activating autoimmunity.
- PAMPs pathogen-associated molecules
- Flagellin can be mixed or genetically fused with a recombinant protein or peptide vaccine. Flagellin also causes an effective immune response at low concentrations. In addition, early exposure of Flagellin does not impair its function as an adjuvant, however, the antigen sequence can be inserted into the amino acid sequence and inserted into the C-terminus, or within its hypervariable region without affecting the activity of Flagellin. Flagellin can also be prepared in large quantities in a simple manner in a GMP environment. For these reasons, flagellin has a significant role as a vaccine adjuvant and immunotherapy.
- the ligation sequence of the helper T cell epitope fragment and the immunostimulatory molecule fragment is as follows: the N-terminus of the immunological checkpoint molecule fragment is linked to the C-terminus of the immunostimulatory molecule fragment, and the immunological checkpoint molecular fragment C The terminus is ligated to the N-terminus of the helper T cell epitope fragment.
- the corresponding molecular fragment in the recombinant protein of the present invention can be presented on the surface of the DC cell, respectively.
- APCs main antigen-presenting cells
- the recombinant protein proposed by the embodiments of the present invention allows DC cells to present intracellular antigens to the cell surface, which is presented to the MHC class II by endocytic pathway, and is presented to the MHC class I by a cross-priming pathway, thereby leading to the production of antigen-specific Th cells. Reacts with CTL cells.
- the recombinant protein presented by the embodiments of the present invention causes a strong antibody response on the surface of DC cells. It has long been believed that the activation of humoral responses by DC cells is achieved by the interaction of T lymphocytes and B lymphocytes by CD4+ Th cells. However, existing in vitro and in vivo experiments have demonstrated that DC cells activate a humoral response as a direct mode of action.
- DC cells have been shown to strongly promote cell differentiation and production of antibodies to CD40-activated B lymphocytes. Inoculation of antigen-loaded DC cells is capable of inducing a protective humoral immune response.
- the recombinant protein of the embodiments of the present invention can more effectively cause a tumor antigen immune response.
- the above recombinant protein has the amino acid sequence of SEQ ID NOS: 1-3.
- SEQ ID NO: 1 is the amino acid sequence of Flagellin-human PD-L1 ⁇ -PADRE Th recombinant protein
- SEQ ID NO: 2 is the amino acid sequence of Flagellin-human PD-L2 ⁇ -PADRE Th recombinant protein
- SEQ ID NO: 3 is Flagellin - Amino acid sequence of human PD-L1-PD-L2 ⁇ -PADRE Th recombinant protein.
- the recombinant protein proposed in the embodiment of the invention can cause tumor-specific antigen immune response, can cause specific killing of cytotoxic T lymphocytes (CTL) and secrete specific antibodies of B cells, and achieve specific killing of tumor cells.
- CTL cytotoxic T lymphocytes
- the present invention proposes a nucleic acid encoding the recombinant protein described above, and according to an embodiment of the present invention, the nucleic acid encoding the recombinant protein described above has the nucleotide sequences shown in SEQ ID NOS: 4 to 6.
- SEQ ID NO: 4 is the nucleotide sequence of the nucleic acid encoding the Flagellin-human PD-L1 ⁇ -PADRE Th recombinant protein
- SEQ ID NO: 5 Is the nucleotide sequence of the nucleic acid encoding the Flagellin-human PD-L2 ⁇ -PADRE Th recombinant protein
- SEQ ID NO: 6 is the nucleotide sequence of the nucleic acid encoding the Flagellin-human PD-L1-PD-L2 ⁇ -PADRE Th recombinant protein.
- the recombinant protein encoded by the nucleic acid proposed in the embodiments of the present invention can cause tumor-specific antigen immune response, cause specific killing of cytotoxic T lymphocytes (CTL) and secrete specific antibodies of B cells, and achieve specificity to tumor cells. Killing.
- CTL cytotoxic T lymphocytes
- the present invention proposes a construct which carries the nucleic acid described above.
- the construct introduced into the recipient cell of the embodiment of the present invention can achieve high-efficiency expression of the nucleic acid described above, thereby efficiently expressing the recombinant protein described above in the recipient cell.
- the vector of the construct is a pET series vector, a pGEX series vector, a pPIC series vector, a BacPAK, a pSV series vector or a pCMV series vector, wherein the pET series vector is in the T7 promoter in E.
- coli Down-regulated expression of recombinant protein pGEX series vectors were used to regulate the expression of recombinant proteins in E. coli under the tac promoter, pPIC series vectors were used to regulate the expression of recombinant proteins in yeast under the AOX1 promoter, and BacPAK vectors were used in Recombinant proteins are expressed in baculovirus under the control of the pPolh promoter, and the pSV series vector or pCMV series vectors are used to express recombinant proteins in mammalian cells under the control of the CMV, SV40 and (EF)-1 promoters.
- the above vector of the embodiment of the present invention can achieve further efficient expression of the above recombinant protein in prokaryotic cells or eukaryotic cells.
- the above construct carries the following nucleic acid molecule: (1) a nucleic acid molecule encoding an immunological checkpoint molecule fragment having the amino acid sequence of SEQ ID NOS: 7-9
- SEQ ID NO: 7 is the amino acid sequence of human PD-L1 ⁇
- SEQ ID NO: 8 is the amino acid sequence of human PD-L2 ⁇
- SEQ ID NO: 9 is the amino acid sequence of human PD-L1-PD-L2 ⁇
- the nucleic acid molecule encoding the immunological checkpoint molecule fragment has the nucleotide sequence shown in SEQ ID NOs: 10 to 12, wherein SEQ ID NO: 10 is the nucleotide sequence of the nucleic acid molecule encoding human PD-L1 ⁇ , SEQ ID NO: 11 is a nucleotide sequence of a nucleic acid molecule encoding human PD-L2 ⁇ , SEQ ID NO: 12 is a nucleotide sequence of a nucleic acid molecule
- the vector of the construct is a prokaryotic or eukaryotic protein expression vector.
- the construct according to the embodiment of the present invention efficiently expresses a recombinant protein containing an immunological checkpoint molecular fragment, a helper T cell epitope fragment and an immunostimulatory molecule fragment in a recipient cell, and the recombinant protein can be significantly caused in a tumor patient.
- the tumor-specific antigen immunoreaction which in turn causes specific killing of cytotoxic T lymphocytes (CTL) and specific antibodies against B lymphocyte secretion, achieves specific killing of tumor cells.
- CTL cytotoxic T lymphocytes
- the present invention also proposes a transgenic cell.
- the transgenic cell carries the construct described above, and the transgenic cell proposed in the embodiment of the present invention can express the recombinant protein as described above to actively stimulate the anti-immunoassay in the patient body by active immunization.
- Point such as antibodies to PD-L1 or PD-L2, mobilize spontaneously induced immune cell CTLs already present in the patient, and stimulate the production of anti-immunological checkpoints, such as PD-L1 or PD-L2 CTL, thereby specifically killing Tumor cells.
- the transgenic cells are BL21, BL21 (DE3), BL21 (DE3) pLysS, DH10B, XL1-Blue, Pichia pastors, Kluyveromyces lactis, Sf9, Sf21, High-Five T, CHO cell line , HEK cell line, Hela cell line or COS cell line.
- BL21, BL21 (DE3), BL21 (DE3) pLysS, DH10B and XL1-Blue are E. coli cells
- Pichia pastors and Kluyveromyces lactis are yeast cells
- Sf9, Sf21, and High-Five T are used for baculovirus.
- CHO cell line, HEK cell line, Hela cell line or COS cell line is a mammalian cell line.
- the transgenic cell can efficiently express the recombinant protein described above, and then the recombinant protein obtained by protein purification can be administered to a patient, and the patient can be further effectively stimulated to produce anti-PD in the patient by active immunization.
- the -L1 or PD-L2 antibody mobilizes spontaneously induced immune cell CTLs already present in the patient and stimulates the production of anti-PD-L1 or PD-L2CTL, thereby specifically killing the tumor cells.
- the transgenic cell can be an antigen presenting cell and the transgenic cell is a DC cell.
- the antigen presenting cell is derived from a patient, and the antigen presenting cell carrying the aforementioned construct can be further input into the patient, thereby realizing the continuous expression of the recombinant protein described above in the patient, and further Actively immunizing in the body to produce anti-PD-L1 or PD-L2 antibodies in vivo, mobilizing the spontaneously induced immune cell CTLs already present in the patient, and stimulating the production of anti-PD-L1 or PD-L2CTL, Specific killing of tumor cells.
- the inventors have proposed the use of the aforementioned recombinant protein for the preparation of a medicament or a vaccine for preventing or treating a tumor.
- the recombinant protein proposed by the embodiments of the present invention can cause a significant tumor-specific antigen immune response in a tumor patient, and effectively stimulates the production of an anti-immunological checkpoint, such as PD-L1 or PD-L2 antibody, to mobilize the spontaneous induction already existing in the patient.
- the resulting immune cell CTL is stimulated to produce an anti-immunological checkpoint, such as PD-L1 or PD-L2CTL, which effectively kills the tumor cells specifically.
- the recombinant protein proposed in the examples of the present invention has a use in the preparation of a medicament or vaccine effective for preventing or treating a tumor.
- the present invention also proposes the use of the aforementioned recombinant protein for the preparation of a vaccine for the treatment of a viral infection.
- the inventors have found that HBV, HCV, HIV, EBV virus-infected cells express PD-L1, and the vaccine prepared by the recombinant protein of the present invention can stimulate anti-PD-L1 in a patient.
- the invention provides a pharmaceutical composition.
- the pharmaceutical composition comprises: the recombinant protein described above; and a pharmaceutically acceptable adjuvant.
- the recombinant protein in the pharmaceutical composition proposed in the examples of the present invention can cause a significant specific antigen immune response, and the function of the adjuvant to enhance the immune response.
- the pharmaceutical composition provided by the embodiment of the present invention effectively stimulates an anti-immunological checkpoint, such as a PD-L1 or PD-L2 antibody, in a tumor patient, and mobilizes the patient already.
- viruses HBV, HCV, HIV, EBV
- the invention provides a DC cell.
- the DC cells are loaded with the recombinant protein described above.
- the DC cells proposed in the embodiments of the present invention can respectively distinguish a tumor antigen (such as the immunological checkpoint molecular fragment described above), a helper T cell epitope group and an immunostimulatory molecule fragment in the recombinant protein.
- anti-immunological checkpoints such as PD-L1 or PD-L2 antibodies
- mobilizes spontaneously induced immune cell CTLs already present in patients and stimulates the production of anti-immune checkpoints, such as PD-L1 Or PD-L2CTL, which in turn effectively kills tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
- viruses HBV, HCV, HIV, EBV
- the invention provides a targeted immune cell population.
- the targeted immune cell population is obtained by co-culture of DC cells with lymphocytes as described above.
- the targeted immune cell population proposed in the embodiments of the present invention can specifically kill tumor cells, secrete antibodies that specifically bind tumor antigens, and achieve specific removal of tumor cells.
- the invention provides a vaccine.
- the vaccine comprises a recombinant protein as described above, a DC cell as described above or a targeted immune cell population as described above.
- the recombinant protein, DC cell, and targeted immune cell population proposed in the examples of the present invention can cause a significant specific antigen immune response in a patient.
- the vaccine according to the embodiment of the present invention can effectively stimulate the production of an anti-immunization checkpoint, such as a PD-L1 or PD-L2 antibody, mobilize the spontaneously induced immune cell CTL already existing in the patient, and stimulate An anti-immunization checkpoint, such as PD-L1 or PD-L2CTL, is generated to effectively kill tumor cells or cells infected with viruses (HBV, HCV, HIV, EBV).
- an anti-immunization checkpoint such as a PD-L1 or PD-L2 antibody
- the invention provides an antibody.
- the antibody specifically recognizes the recombinant protein described above, and the antibody proposed in the embodiment of the present invention specifically recognizes a tumor antigen.
- the present invention finds that the antibody specifically recognizes an antigen, specifically binds to a tumor cell or a cell infected by a virus (HBV, HCV, HIV, EBV), thereby causing a tumor cell or a virus (HBV) , HCV, HIV, EBV) infected cells are engulfed by phagocytic cells to achieve tumor cells or by viruses (HBV, HCV, HIV, EBV) Specific clearance of infected cells.
- a virus HBV, HCV, HIV, EBV
- the present invention proposes a method of preparing an antibody.
- the method comprises: immunizing an animal with the recombinant protein described above; collecting serum of the immunized animal; and purifying the antibody of interest from the serum.
- the method for preparing an antibody proposed in the embodiments of the present invention is simple and convenient, and the antibody can specifically recognize the recombinant protein.
- the therapeutic composition proposed by the present invention may comprise the recombinant protein described above, the nucleic acid described above, the aforementioned construct, the above-described transgenic cell, the aforementioned pharmaceutical composition
- the therapeutic composition proposed by the embodiments of the present invention can directly or indirectly cause a specific antigen immune response, and achieve specificity to tumor cells or cells infected by viruses (HBV, HCV, HIV, EBV). Kill and clear.
- the patient is administered a therapeutically effective amount of the recombinant protein described above, a pharmaceutical composition as described above, a DC cell as described above, a previously described targeted immune cell population, a vaccine as described above, or a front
- the antibodies are effective for treating or preventing tumors expressing PD-L1 or PD-L2.
- administering refers to introducing a predetermined amount of a substance into a patient in some suitable manner.
- the recombinant protein, pharmaceutical composition, DC cell, targeted immune cell population, vaccine or antibody in the embodiments of the present invention can be administered by any common route as long as it can reach the intended tissue.
- Various modes of administration are contemplated, including peritoneal, venous, muscular, subcutaneous, cortical, oral, topical, nasal, pulmonary, and rectal, but the invention is not limited to these exemplary modes of administration.
- the active ingredient of the orally administered composition should be coated or formulated to prevent its degradation in the stomach.
- the compositions of the invention may be administered as an injectable preparation.
- the pharmaceutical compositions of the invention may be administered using a particular device that delivers the active ingredient to the target cells.
- the frequency and dose of administration of the recombinant protein, pharmaceutical composition, DC cell, targeted immune cell population, vaccine or antibody in the examples of the present invention can be determined by a plurality of related factors including the type of disease to be treated. , route of administration, patient age, sex, weight and severity of the disease, and the type of drug as the active ingredient.
- the daily dose may be divided into 1 dose, 2 doses or multiple doses in a suitable form for administration once, twice or more times throughout the time period, as long as a therapeutically effective amount is achieved. .
- terapéuticaally effective amount refers to an amount sufficient to significantly ameliorate certain symptoms associated with a disease or condition, that is, an amount that provides a therapeutic effect for a given condition and dosage regimen.
- treatment is used to mean obtaining the desired pharmacological and/or physiological effect.
- treatment encompasses administration of a recombinant protein, pharmaceutical composition, DC cell, targeted immune cell population, vaccine or antibody in an embodiment of the invention to a subject, including, but not limited to, administration comprising the agents described herein. The individual in need.
- the recombinant protein and the use thereof, the pharmaceutical composition, the DC cell, the targeted immune cell population, the vaccine, the antibody, the method and system for treating and diagnosing cancer according to the embodiment of the present invention are the inventors of the present application. tough Creative labor and optimization work are discovered and completed.
- the method of isolating DC cells from mouse bone marrow is as follows: bone marrow is punched out from the limbs of the mouse, and the bone marrow is passed through a nylon mesh, and red blood cells are removed with ammonium chloride. The cells were then thoroughly washed with RPMI-1640 medium, and then cultured in 2.5 ml of RPMI-1640 medium containing 10% FBS, 20 ng/ml recombinant mouse GM-CSF (rmGM-CSF) and 20 ng/ml. Recombinant mouse IL-4 (rmIL-4) (available from PeproTech, Inc., Rocky Hill, NJ).
- the cell supernatant was removed and fresh medium was replaced with 20 ng/ml of rmGM-CSF and 20 ng/ml of rmIL-4.
- the cells were cultured in an incubator at 37 ° C in a 5% CO 2 atmosphere. At 48 hours of the culture process, non-adherent granulocytes were removed and fresh medium was replaced. After 7 days of cell culture, about 80% or more of the cells expressed DC cell-specific markers by FACS analysis.
- Recombinant protein was added to bone marrow-derived DC cells (obtained after 5-7 days of bone marrow cell culture) to activate DC cells, and after 8 hours, the cells were washed with PBS three times, and after further culture for 136 hours, DC cells were used as Immunization model.
- antigen-activated DC cells were stimulated with 100 ng/ml LPS (Sigma, St. Louis, MO) for 24 hours, and the cells were washed with PBS and injected into mice via the soles of mice (C57BL/6, Jackson). Laboratory) In vivo.
- rodent lung cancer cells CMT167 (C57BL) (purchased from the European Collection of Authenticated Cell Cultures (ECAC)) were introduced into the right abdominal cavity of syngeneic C57BL/6 mice by subcutaneous injection. After tumor inoculation, mice were randomized and injected into antigen-activated DC cells or PBS in different groups on different days. Tumor volume was measured 2 or 3 times a week using a caliper.
- the CD8+ CTL response was assessed by standard chromium release assays.
- Standard chromium release assessment experiments were performed by measuring the ability of spleen cells to lyse target cells in vitro. Splenocytes from immunized mice were restimulated in vitro with RPMI containing the polypeptide for 4 to 6 days. Target cells and control cells were labeled with 51Cr sodium chromate solution for 90 min. Different numbers of effector cells were co-cultured with a certain number (1 ⁇ 104/well) of target cells for 3 hours at 37° C. in a 96-well plate v-bottom plate (200 microliters of medium per well). 100 microliters of supernatant was collected from every 3 wells.
- the dissolution rate is calculated by the following formula: (Experimental chrome release Flux - spontaneous chromium release) / (maximum chromium release - spontaneous chromium release) X 100.
- the amount of chromium released was achieved by co-cultivation, placing the wells on a centrifuge and centrifuging, and calculating the radiation activity in the supernatant by a gamma counter (purchased from Beckman Coulter, Inc., Fullerton, CA) ( Chromium release).
- Synthetic fusion gene one contains the complete Flagellin sequence, partial human PD-L1 sequence or PD-L2 sequence (Accession number GenBank: AF177937.1), and the complete helper T cell PADRE epitope sequence and flanking cloning site sequence ( The fusion gene-structure is shown in Figure 1 (synthesized by GENEWIZ, South Plainfield, NJ, USA).
- Synthetic Fusion Gene 2 Contains a partial human PD-L1 sequence or a PD-L2 sequence (GenBank: AF177937.1) and an intact helper T cell PADRE epitope sequence.
- the target recombinant plasmid was electroporated into Escherichia coli BL21(DE3) (Novagen) competent cells, and then Escherichia coli BL21 (DE3) was seeded on LB agar plates (containing 50 ⁇ g/ml of ampicillin). Amplification culture is carried out.
- the method of recombinant protein expression described below is one of a series of experiments under different experimental conditions.
- the frozen cell pellet was resuspended in lysate (50 mM Tris, pH 8.0, 1 mM EDTA and 1 mM PMSF) with a mass to volume ratio of cell pellet to lysate of 1:10.
- the inclusion bodies containing the recombinant protein were restored to activity under the conditions of French Pressure (Constant Systems LTD) of 137.9 MPa.
- French Pressure Constant Systems LTD
- an equal volume of lysate is added to dilute to reduce viscosity, which is more advantageous for obtaining inclusion bodies.
- the lysed solution was centrifuged at 48,000 x g for 30 min to cause inclusion bodies to precipitate.
- the supernatant was discarded and the pellet was washed three times to remove endotoxin, protein and DNA from the host cells.
- the solution used for the first pass of cleaning contained 50 mM Tris, pH 8.0, 5 mM EDTA and 2% Triton x-100.
- the solution used for the second pass of cleaning contained 50 mM Tris, pH 8.0, 5 mM EDTA, 1% sodium deoxycholate.
- the solution used for the third cleaning consisted of 50 mM Tris, pH 8.0, 5 mM EDTA, and 1 M NaCl. After washing, the pellet was resuspended at room temperature with a special lysate (mass to volume ratio of 1:40), stirred for 30 min and centrifuged.
- the solubilized protein was further purified by a Ni-NTA Fast Start Kit (Qiagen).
- the eluted proteins were analyzed by 12% SDS-PAGE gel electrophoresis, and the protein concentration was determined by Bradford et al. (Bio-Rad Laboratories). Recombinant proteins with a purity greater than 90% were stored at -20 °C for subsequent studies.
- Example 4 DC cells loaded with a fusion protein containing PD-L1 were effective in inducing anti-PD-L1 antibody production and CTL responses in mice.
- the levels of PD-L1-specific IgG in the serum of each group of rats were determined by ELISA, and the recombinant PD-L1 protein (Abeam, Cambridge, MA, USA) was plated every 3 wells of the ELISA plate, and the ELISA value was passed through serum (1). : 100 times dilution) The mean value of OD450nm values ⁇ SD was obtained.
- Figure 2 shows that PD-L1 ⁇ -FljB-loaded DC cells can induce significant anti-PD-L1 antibody responses, whereas PD-L1 ⁇ protein-loaded DC cells can only induce weak anti-PD- L1 antibody reaction.
- spleen cells were isolated from tumor cell suspensions vaccinated with immunized mice.
- the isolated T cells were re-stimulated by PD-L1 recombinant protein-activated DC cells (10 ⁇ g/ml), and then the in vitro 51Cr release test was performed, and the 51Cr release test was performed according to the specified T/E (target cell: effector cell) ratio.
- the target cell was the PD-L1+ murine lung cancer cell line CMT167 (C57BL) (available from the European Collection of Authenticated Cell Cultures (ECACC)).
- Figure 3 shows that PD-L1 ⁇ -FljB-loaded DC cells can induce significant anti-PD-L1CTL responses, whereas DC cells loaded with PD-L1 ⁇ protein induce only weak anti-PD-L1CTL reaction.
- Fig. 4 shows that the immunization of mice with PD-L1 ⁇ -FljB DC was able to significantly inhibit the growth of PD-L1 + lung cancer, but was immunized with DC loaded with protein PD-L1 ⁇ or PBS. Vaccination of mice did not inhibit the growth of PD-L1 + lung cancer.
- the inventors examined DC cells loaded with recombinant protein (Flagellin-human PD-L2 ⁇ -PADRE Th or Flagellin-human PD-L1/L2 ⁇ -PADRE Th) to induce anti-PD-L1 antibodies in mice.
- recombinant protein Flagellin-human PD-L2 ⁇ -PADRE Th or Flagellin-human PD-L1/L2 ⁇ -PADRE Th
- the load Recombinant proteins (Flagellin-human PD-L2 ⁇ -PADRE Th or Flagellin-human PD-L1/L2 ⁇ -PADRE Th) DC cells are capable of inducing significant anti-PD-L1 antibody or anti-PD-L2 antibody responses and inducing significant anti-PD -L1 or anti-PD-L2CTL reaction, after immunization of mice with DC cells loaded with recombinant protein (Flagellin-human PD-L2 ⁇ -PADRE Th or Flagellin-human PD-L1/L2 ⁇ -PADRE Th), can significantly inhibit PD- Growth of L1 + or PD-L2 + lung cancer.
- the load Recombinant proteins (Flagellin-human PD-L2 ⁇ -PADRE Th or Flagellin-human PD-L1/L2 ⁇ -PADRE Th) DC cells are capable of inducing significant anti-PD-L1 antibody or anti-PD-L2 antibody responses and inducing significant anti-PD -L1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne une protéine recombinée et ses utilisations. La protéine recombinée comprend un segment de molécule de point de contrôle immunitaire, un segment d'épitope de lymphocyte T auxiliaire et un segment de molécule immunostimulante.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610222454.2 | 2016-04-11 | ||
CN201610222454.2A CN107286244B (zh) | 2016-04-11 | 2016-04-11 | 抗免疫检查点pd-l1和pd-l2肿瘤疫苗 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017177907A1 true WO2017177907A1 (fr) | 2017-10-19 |
Family
ID=60041416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/080143 WO2017177907A1 (fr) | 2016-04-11 | 2017-04-11 | Vaccins contre les tumeurs pd-l1 et pd-l2 de point de contrôle immunitaire |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107286244B (fr) |
WO (1) | WO2017177907A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019241666A1 (fr) * | 2018-06-14 | 2019-12-19 | Thomas Jefferson University | Vecteur vaccinal codant pour gnaq muté pour le traitement du mélanome uvéal et de cancers ayant des protéines gnaq et gna11 mutées |
US11130787B2 (en) | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116121194B (zh) * | 2023-02-27 | 2023-10-24 | 山东第一医科大学附属肿瘤医院(山东省肿瘤防治研究院、山东省肿瘤医院) | 一种肺癌免疫治疗耐药细胞系及其制备方法和应用 |
CN116850276A (zh) * | 2023-07-06 | 2023-10-10 | 郑州大学第一附属医院 | 一种多靶点免疫检查点肿瘤抗体负荷免疫细胞的肿瘤疫苗及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101002937A (zh) * | 2006-08-23 | 2007-07-25 | 中国人民解放军第四军医大学 | 重组人His-TT-B7-H1IgV肿瘤疫苗及其制备方法 |
CN103965363A (zh) * | 2013-02-06 | 2014-08-06 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2239457T3 (es) * | 1998-09-15 | 2005-09-16 | Pharmexa A/S | Procedimiento para regular a niveles mas bajos la actividad de ligando de osteoprotegerina. |
CN103768604B (zh) * | 2012-10-24 | 2016-03-30 | 北京圣沃德生物科技有限公司 | 治疗性肿瘤疫苗 |
-
2016
- 2016-04-11 CN CN201610222454.2A patent/CN107286244B/zh active Active
-
2017
- 2017-04-11 WO PCT/CN2017/080143 patent/WO2017177907A1/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101002937A (zh) * | 2006-08-23 | 2007-07-25 | 中国人民解放军第四军医大学 | 重组人His-TT-B7-H1IgV肿瘤疫苗及其制备方法 |
CN103965363A (zh) * | 2013-02-06 | 2014-08-06 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
Non-Patent Citations (3)
Title |
---|
CONG, HUA ET AL.: "Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome et al.", IMMUNOME RESEARCH, vol. 12, no. 6, 31 December 2010 (2010-12-31), pages 1 - 15, XP055429034 * |
PENG, XIAOMOU ET AL.: "Effect of exogenous epitopes of helper T lymphocyte on humoral immunity of HBV S gene DNA immunity", NATIONAL MEDICAL JOURNAL OF CHINA, vol. 83, no. 3, 10 February 2003 (2003-02-10) * |
SONG, LI ET AL.: "Progress on Bacterial Flagellin as an Adjuvant", PROGRESS IN VETERINARY MEDICINE, vol. 36, no. 4, 31 December 2015 (2015-12-31) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019241666A1 (fr) * | 2018-06-14 | 2019-12-19 | Thomas Jefferson University | Vecteur vaccinal codant pour gnaq muté pour le traitement du mélanome uvéal et de cancers ayant des protéines gnaq et gna11 mutées |
US11130787B2 (en) | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
Also Published As
Publication number | Publication date |
---|---|
CN107286244A (zh) | 2017-10-24 |
CN107286244B (zh) | 2021-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Porgador et al. | Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. | |
CN105025932B (zh) | 癌疫苗及使用其的治疗方法 | |
JP6134763B2 (ja) | GM−CSF及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 | |
Lin et al. | A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells | |
Wells et al. | Combined triggering of dendritic cell receptors results in synergistic activation and potent cytotoxic immunity | |
JP5087925B2 (ja) | 新規癌抗原ペプチド及びその用途 | |
Tseng et al. | Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts | |
WO2017177907A1 (fr) | Vaccins contre les tumeurs pd-l1 et pd-l2 de point de contrôle immunitaire | |
JP7102430B2 (ja) | 糖尿病の治療のためのペプチド及び方法 | |
CN107488235B (zh) | 一种新的增强型抗原联合多肽诱导肝癌特异性ctl细胞的制备及应用 | |
CN106632694B (zh) | 一种重组蛋白及药物组合物与应用 | |
US10688165B2 (en) | Medicament for use in a method of inducing or extending a cellular cytotoxic immune response | |
Moeini et al. | Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine | |
JP2011506497A5 (fr) | ||
TW201938793A (zh) | 一種新型疫苗佐劑 | |
WO2017177908A1 (fr) | Protéines recombinantes pd-l1 et pd-l2 et leurs utilisations | |
Kollessery et al. | Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model | |
EP1829893B1 (fr) | Formulations inmunotherapeutiques a capacite de neutralisation de l'interleukine-2 | |
Kim et al. | Modification of CEA with both CRT and TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination | |
KR101415554B1 (ko) | 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물 | |
WO2018058489A1 (fr) | Polypeptide antigène tumoral dérivé du cacna1h et son utilisation | |
RU2283129C1 (ru) | Белковопептидный противоопухолевый композит, клеточный препарат, активированный этим композитом, и способ профилактики или лечения опухолей | |
WO2018094570A1 (fr) | Polypeptide et son application | |
CN114790248B (zh) | MUC1-PDL1-IgG1 Fc肿瘤疫苗及其制备方法和应用 | |
WO2018058490A1 (fr) | Polypeptide antigène tumoral dérivé de col14a1 et son utilisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17781883 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17781883 Country of ref document: EP Kind code of ref document: A1 |